Literature DB >> 34584250

Apparent changes in the epidemiology and severity of multiple sclerosis.

Nils Koch-Henriksen1,2, Melinda Magyari3,4.   

Abstract

Multiple sclerosis (MS) is an immunological disease that causes acute inflammatory lesions and chronic inflammation in the CNS, leading to tissue damage and disability. As awareness of MS has increased and options for therapy have come into use, a large amount of epidemiological data have been collected, enabling studies of changes in incidence and disease course over time. Overall, these data seem to indicate that the incidence of MS has increased, but the course of the disease has become milder, particularly in the 25 years since the first disease-modifying therapies (DMTs) became available. A clear understanding of these trends and the reasons for them is important for understanding the factors that influence the development and progression of MS, and for clinical management with respect to prevention and treatment decisions. In this Review, we consider the evidence for changes in the epidemiology of MS, focusing on trends in the incidence of the disease over time and trends in the disease severity. In addition, we discuss the factors influencing these trends, including refinement of diagnostic criteria and improvements in health-care systems that have increased diagnosis in people with mild disease, and the introduction and improvement of DMT.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34584250     DOI: 10.1038/s41582-021-00556-y

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  139 in total

Review 1.  The changing demographic pattern of multiple sclerosis epidemiology.

Authors:  Nils Koch-Henriksen; Per Soelberg Sørensen
Journal:  Lancet Neurol       Date:  2010-05       Impact factor: 44.182

2.  A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway.

Authors:  N Grytten; S B Glad; J H Aarseth; H Nyland; R Midgard; K-M Myhr
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud.

Authors:  C S Simonsen; A Edland; P Berg-Hansen; E G Celius
Journal:  Acta Neurol Scand       Date:  2016-05-30       Impact factor: 3.209

4.  [Experience of treating lichen ruber planus with histaglobin].

Authors:  G I Sukolin
Journal:  Vestn Dermatol Venerol       Date:  1971-07

5.  [Effects of 1,000 rad cephalic irradiation on the cortical bioelectric activity of young rabbits].

Authors:  P Laget; M Kuentz-Desroches; L Court
Journal:  C R Seances Soc Biol Fil       Date:  1971

6.  [Depression of the frontal sinuses. Esthetic and functional repair. Apropos of 2 cases].

Authors:  J Gaillard; M Bouchayer; P Dumolard
Journal:  J Fr Otorhinolaryngol Audiophonol Chir Maxillofac       Date:  1967-05

7.  Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period.

Authors:  E G Celius; B Vandvik
Journal:  Eur J Neurol       Date:  2001-09       Impact factor: 6.089

8.  Schoolgirl mothers.

Authors:  S Tyrrell
Journal:  Nurs Times       Date:  1984 May 23-29

9.  Multiple sclerosis in Nord-Trøndelag County, Norway: a prevalence and incidence study.

Authors:  O P Dahl; J H Aarseth; K M Myhr; H Nyland; R Midgard
Journal:  Acta Neurol Scand       Date:  2004-06       Impact factor: 3.209

10.  Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France.

Authors:  M Debouverie; S Pittion-Vouyovitch; S Louis; T Roederer; F Guillemin
Journal:  Mult Scler       Date:  2007-07-10       Impact factor: 6.312

View more
  10 in total

1.  Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis.

Authors:  Melinda Magyari; Nils Koch-Henriksen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-04-07       Impact factor: 13.654

Review 2.  Vesicle Fusion as a Target Process for the Action of Sphingosine and Its Derived Drugs.

Authors:  José Villanueva; Yolanda Gimenez-Molina; Bazbek Davletov; Luis M Gutiérrez
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

3.  A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.

Authors:  Sepideh Paybast; Seyed Amir Hejazi; Payam Molavi; Mohammad Amin Habibi; Abdorreza Naser Moghadasi
Journal:  Mult Scler Relat Disord       Date:  2022-02-26       Impact factor: 4.808

4.  Effects of non-invasive brain stimulation in multiple sclerosis: systematic review and meta-analysis.

Authors:  Rebecca L D Kan; Grace X J Xu; Kate T Shu; Frank H Y Lai; Gottfried Kranz; Georg S Kranz
Journal:  Ther Adv Chronic Dis       Date:  2022-02-02       Impact factor: 5.091

Review 5.  Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data.

Authors:  Serena Ruggieri; Maria Esmeralda Quartuccio; Luca Prosperini
Journal:  Degener Neurol Neuromuscul Dis       Date:  2022-03-22

6.  Comparison of dimethyl fumarate and interferon outcomes in an MS cohort.

Authors:  Neda Sattarnezhad; Brian C Healy; Moogeh Baharnoori; Camilo Diaz-Cruz; James Stankiewicz; Howard L Weiner; Tanuja Chitnis
Journal:  BMC Neurol       Date:  2022-07-11       Impact factor: 2.903

7.  Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.

Authors:  Huah Shin Ng; Feng Zhu; Elaine Kingwell; Shenzhen Yao; Okechukwu Ekuma; Charity Evans; John D Fisk; Ruth Ann Marrie; Yinshan Zhao; Helen Tremlett
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-06-14

Review 8.  Bibliometric Analysis of Research on the Use of the Nine Hole Peg Test.

Authors:  Gema Moreno-Morente; Miriam Hurtado-Pomares; M Carmen Terol Cantero
Journal:  Int J Environ Res Public Health       Date:  2022-08-15       Impact factor: 4.614

Review 9.  Antibody-mediated cell depletion therapies in multiple sclerosis.

Authors:  Alice Mariottini; Paolo A Muraro; Jan D Lünemann
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

Review 10.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.